1408 ET - Hims & Hers Health's stock will continue to be closely tied to the growth of its weight-loss business, despite its expansion into testosterone treatments, Leerink Partners analysts say in a note. The company's testosterone offerings have been long-awaited, and should help it sustain growth, particularly into next year and beyond, the analysts say. But ultimately shares will be more closely tied to the durability and upside potential of its weight management offerings, they say. Hims' weight loss business has come under pressure in recent months with the FDA declaring an end to the shortage of obesity treatments like Ozempic and Zepbound, which had allowed the company to sell compounded versions of the drugs. (kelly.cloonan@wsj.com)

(END) Dow Jones Newswires

September 10, 2025 14:08 ET (18:08 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.